Compare Moody's Corporation (MCO) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moody's Corporation vs Pfizer Inc — how do they compare? Moody's Corporation trades at $462.42 (market cap $79.44B), while Pfizer Inc trades at $27.93 (market cap $158.56B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Moody's Corporation for 132 Days and Pfizer Inc for 158 Days on average.
| MCO | PFE | |
|---|---|---|
Market Cap | $79.44B | $158.56B |
Volume | 526,684 | 44,138,282 |
Sector | Financials | Health |
52-Week High | $539.61 | $29.02 |
52-Week Low | $412.23 | $23.67 |
Typical Hold Time | 132 Days | 158 Days |
Enterprise Value | $85.46B | $210.06B |
Dividend Yield | 0.9% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCO trades at $460.91, up 2.51% today, with a bearish technical signal but strong fundamentals including a 34.25% net income margin and consistent earnings beats. Revenue grew from $5.5B in 2022 to $7.7B in 2025, with a consensus analyst price target of $536.40. Recent news highlights a Zacks upgrade to Buy and a minority stake acquisition in PhilRatings to expand Asia-Pacific presence.
The outlook is positive given robust profitability and growth, but risks include high valuation multiples and technical weakness. Analysts are predominantly bullish, with 56% Buy ratings, suggesting upside potential if earnings momentum continues, though investors should monitor debt levels and market sentiment shifts.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
